Trial reportStem cell research & therapy2025
Mesenchymal stem cells combined with IFN-γ treatment versus mesenchymal stem cells monotherapy: safety and efficacy over five years extension follow-up.
Trial report in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HuMSCs-derived exosomes alleviate premature ovarian insufficiency by enhancing SIRT3-mediated mitochondrial function in theca-interstitial cells.Journal of ovarian research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo report long-term safety and efficacy of mesenchymal stem cells (MSCs) in combination with and without IFN-γ in patients with rheumatoid arthritis (RA), using pooled data from two randomised clinical trials followed by long-term extension (LTE) study.
methodsCumulative data from two phase 1/2 core trials and their LTE studies were analysed. Safety variables assessed included treatment-emergent adverse events (AEs), serious AEs (SAEs) and laboratory results. Efficacy assessments included ACR20/50/70 responses, Disease Activity Score 28 < 2.6 (remission) and ≤ 3.2 (LDA, low disease activity).
resultsA total of 110 patients received MSCs monotherapy and MSCs combined with IFN-γ treatment. Event rates per 100 patient-years in MSCs monotherapy group and MSCs combined with IFN-γ treatment group, respectively, were 2.47 and 2.31 for SAEs. No increase in the rate of any AE was observed over five years. Clinical response rates remained stable during the LTE study. Initial improvements in LDA/remission observed at year one were sustained over five years of follow-up in both groups, while the MSCs combined with IFN-γ treatment group had higher ACR20 and LDA rates than the MSCs monotherapy group at both one year (100% versus 50.7%, p < 0.001; 39.3% versus 8.7%, p < 0.001) and five years (89.3% versus 44.9%, p < 0.001; 42.9% versus 8.7%, p < 0.001).
conclusionThe long-term safety and efficacy of MSCs with/without IFN-γ combination therapy remained stable. The efficacy of MSCs was maintained through at least five years. These findings support MSCs as a treatment option for patients with active RA.
trial registrationChiCTR-ONC-16,008,770 (2016-07-03) and ChiCTR-INR-17,012,462 (2017-08-24).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.